New Progress in China’s GLP-1 Receptor Agonists: Insights into Ecnoglutide, Visepegenatide, and Mazdutide

In recent years, as the prevalence of type 2 diabetes and obesity continues to rise, GLP-1 receptor agonists (GLP-1 RAs) have become a key growth area in metabolic therapy. China’s domestic innovation in this field is also accelerating, with several differentiated products emerging. Among them, Ecnoglutide Injection, Visepegenatide Injection, and Mazdutide Injection are currently regarded as some of the most noteworthy Chinese GLP-1 innovative therapies.

Amid the ongoing integration of the global pharmaceutical supply chain, professional medical supply service providers—including Hong Kong Dengyue Med—are also paying increasing attention to promoting the international circulation and market connectivity of China’s innovative metabolic drugs, further raising industry visibility.

I. Why Are GLP-1 Receptor Agonists Receiving So Much Attention?

GLP-1 RAs work by mimicking the body’s natural glucagon-like peptide-1, delivering multiple metabolic benefits:

● Stimulate glucose-dependent insulin secretion

● Suppress glucagon release

● Delay gastric emptying

● Increase satiety and support weight management

Compared with some traditional glucose-lowering drugs, this class generally offers a lower risk of hypoglycemia, weight benefits, and potential cardiometabolic advantages. As a result, market interest continues to grow.

II. Key Analysis of Three Chinese GLP-1 Innovative Drugs

1. Ecnoglutide Injection

Drug type: Long-acting GLP-1 receptor agonist

Primary use: Glycemic management in type 2 diabetes

Mechanism features

Ecnoglutide selectively activates the GLP-1 receptor to enhance insulin secretion and suppress glucagon, while also slowing gastric emptying and reducing appetite, achieving multi-pathway glucose control.

Product highlights

✔ Long-acting dosing design that may improve adherence

✔ Potential for weight management benefits

✔ Low hypoglycemia risk profile

✔ Suitable for patients needing intensified glycemic control

Overall:

Ecnoglutide reflects an important shift of domestic GLP-1 therapies toward longer-acting formulations.

2. Visepegenatide Injection

Drug type: Next-generation GLP-1 analog

Indication focus: Type 2 diabetes

Molecular optimization strategy

● Visepegenatide has been structurally optimized to:Extend in-vivo duration

● Improve receptor selectivity

● Enhance gastrointestinal tolerability

Potential advantages

✔ More stable glycemic control curve

✔ Attractive for patients concerned with weight management

✔ May reduce early GLP-1–related GI reactions

✔ Supports individualized treatment strategies

Overall:

Visepegenatide represents the GLP-1 field’s evolution toward a more comfortable treatment experience.

3. Mazdutide Injection

Drug type: GLP-1/GIP dual receptor agonist

R&D positioning: Next-generation metabolic therapy

Among the three, this drug features the most advanced mechanism.

Dual-target mechanism

●  Mazdutide simultaneously activates:GLP-1 receptors

● GIP receptors

This may produce synergistic metabolic effects, including:

● Stronger glucose-lowering potential

● More significant weight management effects

● Broader metabolic improvement

Competitive advantages

⭐ Dual-target design (industry hotspot)

⭐ Strongly watched weight-loss potential

⭐ Represents next-generation metabolic therapy

⭐ Rapidly rising market attention

From an R&D perspective:

Mazdutide is viewed as an important Chinese exploration in dual-target metabolic drugs.

III. Industry Trend Observations

From the development paths of these three products, several clear trends are emerging in China’s GLP-1 landscape:

✅ Long-acting therapies becoming mainstream

Dosing frequency continues to decrease, improving patient adherence.

✅ Acceleration toward multi-target mechanisms

The field is evolving from single GLP-1 to GLP-1/GIP dual-target approaches.

✅ Dual focus on glycemic control and weight management

Weight outcomes have become a key competitive dimension.

✅ Domestic innovation entering the fast lane

Chinese companies are significantly strengthening their metabolic R&D capabilities.

During this process, pharmaceutical supply chain participants such as DengyueMed are supporting more efficient market access for innovative drugs through multi-source procurement, cold-chain capabilities, and compliance system development.

IV. Potential Clinical Use Populations (Physician-Evaluated)

In real-world practice, physicians may consider GLP-1 therapies when:

● Type 2 diabetes is inadequately controlled

● Patients are overweight or obese

● Lower hypoglycemia risk is desired

● Oral therapies are insufficient

● Comprehensive metabolic management is needed

⚠️ Specific medication decisions must be made by qualified healthcare professionals based on individual patient conditions.

V. Conclusion

Overall, Ecnoglutide Injection, Visepegenatide Injection, and Mazdutide Injection represent three important directions in China’s GLP-1 receptor agonist development:

● Long-acting optimization

● Improved treatment experience

● Dual-target metabolic advancement

As more clinical data accumulate and globalization progresses, Chinese GLP-1 innovations are expected to play an increasingly important role in the global metabolic therapy landscape. Meanwhile, professional pharmaceutical supply service providers—including Hong Kong Dengyue Pharmaceutical—are likely to serve as important bridges connecting Chinese innovative drugs with the global market.